Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
After publishing: 6 headlines quietly rewritten, 2 descriptions edited, 1 URL changed9 changes
- El País (Spain)seen 19 Aug, 21:52headline rewritten
El anuncio del éxito de la primera vacuna contra el melanoma dispara las acciones de Moderna y MerckModerna y Merck anuncian el éxito de la primera vacuna personalizada contra el melanoma y sus acciones se disparan en Bolsa - El Mundo (Spain)seen 19 Aug, 21:52description edited
what the description said, before and after
El anuncio se ha difundido en una nota de prensa, no en una publicación científica. Según sus datos, se trata del primer éxito en fase 3 para una terapia oncológica basada en ARNm, Combinada con una inmunoterapia, reduce el riesgo de recaída en pacientes con este cáncer de piel LeerEl anuncio se ha difundido en una nota de prensa, no en una publicación científica. Según sus datos, se trata del primer éxito en fase 3 para una terapia oncológica basada en ARNm. Combinada con una inmunoterapia, reduce el riesgo de recaída en pacientes con este cáncer de piel Leer
- ANSA (Italy)seen 19 Aug, 21:52headline rewritten
Il vaccino contro il melanoma mostra risultati promettenti, Moderna vola in Borsa a +130%Successo del farmaco antimelanoma, Moderna strappa a Wall Street - Libération (France)seen 20 Aug, 17:56headline rewritten
Cancer de la peau : un vaccin à ARN messager testé par Moderna et Merck pourrait diminuer de manière «significative» le risque de récidiveCancer de la peau : un vaccin à ARN messager testé par Moderna et Merck pourrait repousser de manière «significative» la récidive - businessday.co.zaseen 21 Aug, 16:33headline rewritten
Moderna shares up 60% as melanoma vaccine trial with Merck succeedsModerna shares surge as melanoma vaccine trial with Merck succeeds - ANSA (Italy)seen 21 Aug, 23:48URL changed
- Libération (France)seen 23 Aug, 05:07headline rewritten
Cancer de la peau : un vaccin à ARN messager testé par Moderna et Merck pourrait repousser de manière «significative» la récidiveCancer de la peau : un vaccin à ARN messager testé par Moderna et Merck pourrait diminuer de manière «significative» la récidive - ABC (Spain)seen 24 Aug, 16:25headline rewritten
Lo que aún no sabemos de la vacuna que quiere revolucionar el tratamiento del cáncer contra el melanomaLas claves de la vacuna contra el melanoma - South China Morning Postseen 26 Aug, 09:03description edited
what the description said, before and after
A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna’s breakthrough cancer vaccine trial, as the Chinese companies push forward with similar vaccine programmes. The companies – from Jiangsu Hengrui Pharmaceuticals to Li Ka-shing-backed CK Life Sciences – already have a slew of cancer vaccines in development, which could have a large potential market given that nearly 2.6 million people die from cancer in China alone each year. “China is...A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna’s breakthrough cancer vaccine trial, as the Chinese companies push forward with similar vaccine programmes. The companies – from Jiangsu Hengrui Pharmaceuticals to Li Ka-shing-backed CK Life Sciences – already have a slew of cancer vaccines in development. “China is moving quickly and has already built a large pipeline of more than 100 cancer vaccine programmes,” said Cui Cui, head of...
After the peak, new reports halved every 31 hours so far - this story is still being covered, so the figure moves as reports arrive.
What it is about
Who published it, and when
+ 1 more outlet · 36 reports left out of the cascade - too little in common with the story to place
How it spread - 65 original reports, 1 reprint
Wed, 19 August 2026
31 reports- merck.com10:45
First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA Intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed specifically for...
- Google News - Top Stories10:46first to report
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90% CNBC Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma NBC News World in Brief: trials show promise for a skin-cancer vaccine; Trump pauses Canada tariffs The Economist Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With...
- theglobeandmail.com11:18
Interim analysis shows goals were met for recurrence and preventing cancer spread
- Vecernji list (Croatia)11:54
Ako se učinkovitost personaliziranog cjepiva potvrdi i u daljnjim ispitivanjima, terapija bi mogla predstavljati novu mogućnost za pacijente s visokorizičnim melanomom, ali i otvoriti vrata primjeni sličnog pristupa kod drugih vrsta raka.
- businessday.co.za13:05edited after publishing
previously
Moderna shares up 60% as melanoma vaccine trial with Merck succeedsInterim analysis shows goals were met for recurrence and preventing cancer spread
- Google News - Top Stories13:08
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial Reuters Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90% CNBC Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here's what's happening Fast Company MRNA Stock Heads For Its Best Ever Day After Melanoma Therapy Meets Primary Goal Yahoo Finance Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma NBC News
- France Info (France)13:27
Leur thérapie, combinée à l'immunothérapie Keytruda, a amélioré de manière "statistiquement significative" la survie sans récidive chez des patients ayant un mélanome de stade avancé, et préalablement opérés.
- El País (Spain)13:57edited after publishing
previously
El anuncio del éxito de la primera vacuna contra el melanoma dispara las acciones de Moderna y MerckEl avance se ha difundido en una nota de prensa en la que no se ofrecen datos concretos de mejora de supervivencia. De confirmarse, se trataría de un hito histórico
- El Mundo (Spain)14:17edited after publishing
El anuncio se ha difundido en una nota de prensa, no en una publicación científica. Según sus datos, se trata del primer éxito en fase 3 para una terapia oncológica basada en ARNm. Combinada con una inmunoterapia, reduce el riesgo de recaída en pacientes con este cáncer de piel Leer
- Google News - Top Stories14:18
Moderna Shares Double on Success of mRNA Cancer Vaccine WSJ Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90% CNBC Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STAT Cancer treatment could face landmark moment with promising vaccine The Washington Post Moderna and Merck Revive mRNA Hopes With Melanoma Trial Success Bloomberg.com
- ABC (Spain)14:49
La promesa de adiestrar al sistema inmunitario con la misma tecnología que combatió al Covid-19 para que destruya las células tumorales de forma individualizada acaba de cruzar una línea definitiva. Los laboratorios farmacéuticos estadounidenses Merck y Moderna han anunciado este miércoles buenas noticias en la fase final de los ensayos clínicos de su vacuna experimental con ARN mensajero para el cáncer de piel, dirigido a pacientes con melanoma avanzado. «Se trata del primer anuncio de...
- The Hill14:54
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and...
- South China Morning Post14:56
US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer patients when used with Merck’s Keytruda treatment, the companies said in a statement. Unlike conventional vaccines, so-called therapeutic vaccines like intismeran treat rather...
- Index.hr (Croatia)15:08
OPTIMIZAM zbog mogućeg velikog napretka u personaliziranom liječenju raka doveo je do udvostručenja vrijednosti dionica Moderne.
- Anadolu Agency (AA)15:23
Merck and Moderna’s personalized cancer vaccine delivered positive results in its first phase 3 trial
- abcnews.com15:41
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment
- Wirtualna Polska (Poland)15:58
Spersonalizowana szczepionka mRNA przeciwko czerniakowi, stosowana łącznie z immunoterapią, przynosi obiecujące wyniki w badaniu klinicznym III fazy obejmującym ponad tysiąc pacjentów. Jak podaje PAP, terapia istotnie wydłuża czas przeżycia bez nawrotu choroby w porównaniu z leczeniem samą immunoterapią.
- Google News - Top Stories16:10
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma NBC News Cancer treatment could face landmark moment with promising vaccine The Washington Post Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss Bloomberg.com Moderna and Merck Say mRNA Vaccine Prevents Melanoma From Returning The New York Times Moderna shares surge as melanoma vaccine with Merck succeeds in large trial CNN
- ABC News (Australia)16:19
A trial of more than 1,100 patients finds a new experimental drug could prevent one of the deadliest forms of skin cancer from returning.
- ANSA (Italy)16:26
Sviluppato con Merck raggiunge obiettivi chiave dello studio in fase avanzata
- ANSA (Italy)16:26edited after publishing
previously
Il vaccino contro il melanoma mostra risultati promettenti, Moderna vola in Borsa a +130%Sviluppato con Merck si basa sulla tecnologia mRNA utilizzata contro il Covid
- Il Fatto Quotidiano (Italy)16:46
Le azioni di Moderna volano a Wall Street dopo i risultati positivi dello studio di fase 3 sul vaccino a mRNA contro il melanoma sviluppato insieme a Merck. Il titolo della società biotech americana è arrivato a guadagnare oltre il 130%, superando quota 145 dollari, mentre Merck, partner del progetto e produttrice dell’immunoterapico Keytruda, ha […] L'articolo “Risultati promettenti” per il vaccino a mRna contro la recidiva del melanoma. Le azioni di Moderna volano in Borsa proviene da Il...
- Google News - Top Stories16:53
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say Ars Technica Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 150% CNBC CancerBuddy creator on ways to connect KTVU A New mRNA Vaccine Could Prevent Melanoma From Returning The New York Times MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score Clinical Trials Arena
- Die Zeit (Germany)17:06
Moderna hat positive Studiendaten zu einer neuartigen Melanom-Impfung veröffentlicht. Die mRNA-Impfung könnte demnach die Ausbreitung von Hautkrebs bremsen.
- Der Spiegel (Germany)18:27
Mit seinen Covid-Vakzinen machte das US-Pharmaunternehmen Moderna sich weltweit einen Namen. Nun hofft es, mit einer Vakzine gegen Hautkrebs daran anknüpfen zu können. Eine Studie weckt jetzt neue Hoffnungen.
- bbc.co.uk19:00
A new jab extended the length of time patients were cancer free, but it is unclear for how long.
- RMF24 (Poland)19:58
Niezwykły skok na giełdzie. Okazało się, że szczepionka daje dobre wyniki w leczeniu czerniaka
- ksyl.com20:00
Stock photo of a doctor examining a patient's skin. (Lordhenrivoton/STOCK PHOTO/Getty Images)(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans.In Phase 3 trials, the...
1 reprint
- abc7news.com19 Aug, 17:37their copy
- Axios20:04
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards. The customized therapy, which could see a commercial launch next year,...
- Al Jazeera English20:39
Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
- MercoPress (South America)21:47
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients. It is the first positive result at that stage for an mRNA-based cancer treatment.
Thu, 20 August 2026
16 reports- Japan Times01:37
The treatment involves pairing Merck's immunotherapy drug with a customized mRNA vaccine that instructs the immune system to attack specific cancer cells.
- thevermilion.com06:47
The technology of mRNA vaccines which transformed Moderna into one of the symbols of the pandemic could now open a new path in the fight against cancer. The US company and Merck have announced positive ... Read more
- Tagesschau (Germany)08:10
Mit der Entwicklung eines mRNA-basierten Impfstoffes könnte den US-Konzernen Merck und Moderna ein Erfolg in der Behandlung von schwarzem Hautkrebs gelungen sein. Finale Ergebnisse einer klinischen Studie machen Hoffnung.
- Libération (France)09:53edited after publishing ×2
previously
Cancer de la peau : un vaccin à ARN messager testé par Moderna et Merck pourrait repousser de manière «significative» la récidiveLe 19 août, les laboratoires américains ont fait part de résultats encourageants à la suite d’un essai clinique mené sur plus de 1 000 patients. Deux chercheurs français, qui n’ont pas participé à ces travaux, saluent une «bonne nouvelle» en attendant de voir les données complètes de l’étude.
- France Info (France)10:01
Les laboratoires Moderna et Merck ont annoncé les premiers résultats d'un vaccin destiné à lutter contre les rechutes du cancer de la peau. S'il faut encore attendre les données consolidées, l’oncologue Suzette Delaloge détaille le fonctionnement de médicament très innovant.
- Tagesschau (Germany)12:34
Die beiden US-Pharma-Unternehmen Moderna und Merck haben möglicherweise einen Durchbruch bei einem potenziellen Impfstoff gegen schwarzen Hautkrebs erreicht. Das kommt bei Anlegern und Analysten gut an.
- ČT24 (Czechia)12:53
Společnost Moderna ve spolupráci s farmaceutickou firmou Merck vyvinula personalizovanou terapii proti rakovině, která v pokročilé fázi klinického testování v kombinaci s přípravkem Keytruda snížila riziko návratu a šíření melanomu. Nová léčba je téměř o polovinu účinnější než doposud používané léky. Pokud dojde ke schválení, mohla by výrazně zvýšit pravděpodobnost lidí po operaci melanomu, že se jim nemoc už nevrátí.
- Google News - Top Stories13:31
Moderna and Merck shares soar on mRNA cancer vaccine Axios How Moderna Nearly Tripled Its Stock Price in a Single Day The New York Times What Moderna’s vaccine trial results might mean for the future of cancer care The Boston Globe Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBC Moderna’s 177% Surge Burns Shorts in ‘Painful’ $5.5 Billion Loss Bloomberg.com
- americanbazaaronline.com14:08
AI-powered personalized cancer vaccine shows promising melanoma trial results, highlighting software-driven advances in treatment.
- Die Zeit (Germany)14:16
Moderna berichtet von neuen Ergebnissen seiner mRNA-Impfung gegen Hautkrebs. Wie das Medikament funktioniert, wann es kommt und ob es die Krebsbehandlung revolutioniert.
- PBS NewsHour14:49
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
- Anadolu Agency (AA)15:56
Companies report promising results for personalized vaccine aimed at reducing melanoma recurrence
- El País (Spain)16:12
Centros de Barcelona, Madrid, Málaga y Valencia fueron escenario de este hito médico
- Google News - Top Stories17:28
Why Is Moderna Stock Down Today? Forbes Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBC Moderna’s 177% Surge Burns Shorts in ‘Painful’ $5.5 Billion Loss Bloomberg.com Moderna’s Shift to Cancer Company Lifts Stock Up 177% The New York Times Moderna, Merck breakthrough could usher in wave of cancer vaccines Reuters
- Le Monde (France)17:31
La biotech et le laboratoire Merck ont annoncé, mercredi 19 août, avoir obtenu des résultats probants dans la lutte contre le mélanome, lors de la dernière phase d’un essai clinique. En réaction, l’action Moderna a quasi triplé en une séance boursière.
- prevention.com18:30
Doctors break down what you need to know.
Fri, 21 August 2026
3 reports- El País (Spain)03:30
El anuncio, aún impreciso, de una vacuna exitosa contra el melanoma supone un hito en la carrera para frenar esta enfermedad
- Google News - Top Stories03:55
Opinion | The cancer vaccine interrupts a technology backlash The Washington Post Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBC Moderna’s Shift to Cancer Company Lifts Stock Up 177% The New York Times How Moderna’s Historic Short Squeeze Upended the AI Chip Trade Barron's Moderna’s 177% Surge Burns Shorts in ‘Painful’ $5.5 Billion Loss Bloomberg.com
- Channel News Asia11:30
The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available and why researchers hope the approach can be used against other cancers.
Sun, 23 August 2026
5 reports- Google News - Top Stories00:31
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink WSJ Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math WSJ What it was like to go through a trial that could revolutionize cancer treatment The Washington Post Moderna, Merck breakthrough could usher in wave of cancer vaccines CNN A New mRNA Vaccine Could Prevent Skin Cancer From Returning The New York Times
- El País (Spain)03:30
Tras décadas de fracasos, un tratamiento frente al melanoma está muy cerca de aprobarse
- Google News - Top Stories09:30
Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math WSJ Moderna, Merck breakthrough could usher in wave of cancer vaccines CNN Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope Reuters It now seems possible to vaccinate against cancer The Economist Opinion | A cancer vaccine would be a miracle of science — and the free market The Washington Post
- Google News - Top Stories16:00
Cancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential CNN See more headlines & perspectives on Google News
- ABC (Spain)23:30edited after publishing
previously
Lo que aún no sabemos de la vacuna que quiere revolucionar el tratamiento del cáncer contra el melanomaNunca como este año se ha esperado con tanta expectación la cita de ESMO, el Congreso de la Sociedad Europea de Oncología Médica. La reunión tendrá lugar en Madrid, del 23 al 27 de octubre, y se espera que las farmacéuticas Moderna y MSD (Merck en Estados Unidos) muestren datos concretos de una de las investigaciones más esperadas: el ensayo de la primera vacuna de ARN contra el melanoma.La semana pasada las dos compañías lanzaron un aperitivo de sus progresos al anunciar que su ensayo había...
Mon, 24 August 2026
2 reports- El Pais English16:25
After decades of setbacks, a treatment for melanoma is very close to being approved
- Vecernji list (Croatia)17:44
Dodatak cjepiva terapiji statistički je značajno i klinički relevantno produljio vrijeme bez vraćanja bolesti i bez pojave udaljenih metastaza
Tue, 25 August 2026
3 reports- wbur.org14:55
Moderna's stock price soared last week after the release of promising news about an experimental melanoma treatment using an mRNA-based cancer vaccine that the Cambridge company is working on with Merck. Two local cancer researchers explain how the treatment works and how it could mean for their field.
- sciencenews.org16:00
A personalized mRNA vaccine paired with Keytruda may help keep skin cancer from returning after surgery, a large clinical trial suggests.
- arynews.tv20:12
Interim data from a large trial showed the experimental vaccine, when combined with Merck's blockbuster immunotherapy Keytruda, helped
Wed, 26 August 2026
4 reports- South China Morning Post01:00edited after publishing
A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna’s breakthrough cancer vaccine trial, as the Chinese companies push forward with similar vaccine programmes. The companies – from Jiangsu Hengrui Pharmaceuticals to Li Ka-shing-backed CK Life Sciences – already have a slew of cancer vaccines in development. “China is moving quickly and has already built a large pipeline of more than 100 cancer vaccine programmes,” said Cui Cui, head of...
- newsday.com06:00
Long Island is playing even a small role in the discovery is important.
- jhu.edu17:30
Study of an experimental alternative to the industry standard suggests therapeutics could be delivered faster and more efficiently
- El Mundo (Spain)20:44
Las vacunas de ARNm personalizadas podrían no tener un alcance tan amplio ni resultar tan lucrativas como se esperaba Leer
Thu, 27 August 2026
1 report- weekendpost.co.bw10:40
A breakthrough in the fight against melanoma, the deadliest form of skin cancer, has just been announced. A revolutionary new vaccine, developed by pharmaceutical giants Moderna and Merck, promises to slash the risk of dying from this aggressive disease by nearly half. This is not just any vaccine; it is a personalized mRNA jab, custom-designed for each patient in a matter of weeks, that trains the immune system to hunt down and destroy cancer cells...